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Abstract 
Interferon (INF)-associated retinopathy occurs in 15–64% of INF-treated patients, 
transforming this complication into a significant risk for visual impairment. This 
retinopathy has been described as an ocular complication with a variable clinical course, 
usually benign and asymptomatic. The most common findings are hemorrhages and 
cotton wool spots. Atypical ocular side effects include branch or central retinal artery 
occlusion, central retinal vein occlusion, anterior ischemic optic neuropathy, optic disc 
edema, neovascular glaucoma and vitreous hemorrhage. Some case series suggest that 
in most cases the clinical course of the disease is benign, asymptomatic and without 
long-term consequences and therefore do not recommend any specific treatment; they 
only recommend the discontinuation of INF in patients with severe manifestations or risk 
factors such as hypertension or diabetes mellitus. The case reported here presents an 
atypical manifestation of INF-associated retinopathy consisting of a mixed retinal 
vascular occlusion (arterial and venous), associated with severe occlusive inflammatory 
microangiopathy with extensive retinal damage by ischemia and a torpid clinical course 
despite suspension of treatment. These varieties of occlusive vascular events have not 
yet been found simultaneously in the literature and neither with an unfavorable clinical 
course. Although the clinical course of INF-associated retinopathy in most cases is 
asymptomatic, there may be complications with risk to vision, which is less common. The 
magnitude and severity of the consequences associated with INF therapy are to be 
determined in prospective further studies. 
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Introduction 
Chronic infection with hepatitis C virus is estimated to affect almost 4 million people 
in the USA, 5 million in Europe, and 170 million worldwide [1]. Interferon (INF)-
associated retinopathy occurs in 15–64% of INF-treated patients [2, 7], transforming this 
complication into a significant risk factor for visual impairment. 
Pegylated INF (peg-INF) is a complex of proteins with antiviral, antiproliferative and 
immunomodulatory activity, which is used in combination with ribavirin for the 
treatment of chronic hepatitis C in adult patients [5, 6]. INF-associated retinopathy has 
been reported as an ocular complication with variable clinical course, which is usually 
benign and asymptomatic [3, 4]. We report an unusual case of unilateral INF-associated 
retinopathy in a patient who presented with a mixed retinal vascular occlusion connected 
with severe visual impairment. 
Case Report 
A 45-year-old female, treated for 4 months with peg-INF α2a (180 μg weekly) and ribavirin (1,000 
mg daily) for hepatitis C and diagnosed 1 year previously, presented with sudden painless visual loss in 
the left eye. Her general health did not show any other alterations. The presence of diabetes, 
hypertension and other risk factors (cardiovascular or systemic) was ruled out by an Internal Medicine 
doctor. Ocular examination showed visual acuity of 20/20 in the right eye and counting fingers in the 
left eye. The anterior segment did not show any alteration. Intraocular pressure in the right eye was 13 
and in the left eye 8. Fundoscopy in the right eye was normal. The left eye revealed retinal vessel 
tortuosity, multiple flame hemorrhages at the posterior pole, cotton wool spots and superior temporal 
retinal pallor. Fluorescein angiography revealed delayed arterial and venous filling, large areas of 
ischemia in the superior quadrants, retinal hemorrhages, periphlebitis, macular edema, upper trunk 
venous occlusion and lower trunk venous stasis associated with occlusion of the superior temporal 
arterial branch (fig. 1). Optical coherence tomography (OCT) showed macular thickening (626 μm) 
secondary to diffuse edema and presence of microcysts (fig. 2). 
INF and ribavirin were discontinued, and the patient was given 2 doses of intravitreal avastin 
injection with a 1-month interval. She presented with visual improvement in the left eye (20/60) and 
decreased macular retinal thickness (322 μm) (fig. 3). Four months later, she showed sudden visual loss 
in the left eye. Ocular examination revealed visual acuity of hand movement, superior peripapillary 
fibrovascular proliferation and retinal hemorrhages. Large areas without capillary perfusion in the 
upper quadrants, neovascularization and diffuse macular edema were found in the control 
angiographies (fig. 4). 
Although retinal photocoagulation was performed in the affected quadrant, 5 months later, 
tractional retinal detachment became apparent, which was treated with posterior vitrectomy. After 3 
years of follow-up, best-corrected visual acuity in the left eye was 20/400, the anterior segment exhibited 
no changes, and fundoscopy showed optic disc pallor, superior retinal atrophy, and macular hole 
(fig. 5). 
Discussion 
Ocular side effects of treatment with INF and ribavirin for hepatitis C are well known. 
The most common findings are hemorrhages and cotton wool spots. Other findings are 
hyperemia of the disc and macular edema [3]. Atypical ocular side effects reported in 
connection with the use of INF include branch retinal artery occlusion, central retinal 
vein occlusion, Vogt-Koyanagi-Harada-like disease [5], anterior ischemic optic 
neuropathy [5, 9], retinal detachment, subconjunctival hemorrhage, optic disc edema,  
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neovascular glaucoma, vitreous hemorrhage [10], panophthalmitis [4, 5], and central 
retinal artery occlusion [11]. The common denominator of these atypical severe 
manifestations of INF-associated retinopathy is complete and permanent visual loss 
despite discontinuation of treatment and proper ophthalmological management [5, 9]. 
Some case series suggest that in most patients, the clinical course of the disease is 
benign, asymptomatic, and without long-term consequences and therefore do not 
recommend any specific treatment; they only recommend the discontinuation of INF 
treatment in patients with severe manifestations or risk factors such as hypertension or 
diabetes mellitus [3, 6, 7]. 
The exact pathophysiological mechanism due to which retinopathy develops is 
unknown. Similarities with some characteristics of diabetic and hypertensive retinopathy 
suggest an ischemic mechanism. Other authors suggest that immune complex deposits in 
the vessels lead to retinal capillary perfusion failure and the formation of cotton wool 
spots [3, 7]. The increase in photocoagulated phospholipids in hepatitis C causes a 
hypercoagulable state when combined with INF-α, inducing production of thrombogenic 
autoantibodies. Recent studies have found a linkage between INF-associated retinopathy 
and elevated serum levels of vascular endothelial growth factor (VEGF). The appearance 
of elevated VEGF levels is correlated with activation of angiogenesis, but its role in the 
pathogenesis of retinopathy is still unclear [6, 7]. 
The case reported here presents an atypical manifestation of INF-associated 
retinopathy consisting of a mixed retinal vascular occlusion (arterial and venous), 
associated with severe occlusive inflammatory microangiopathy with extensive retinal 
damage by ischemia and a torpid clinical course despite suspension of treatment. Case 
reports of this variety of occlusive vascular events have not yet been found in the 
literature, nor have such cases with an unfavorable clinical course been found, which 
challenge the generally accepted concept that retinopathy has a benign clinical course 
with a low risk of functional compromise and a self-limited course. 
In the differential diagnosis, the presence of thrombotic or embolic retinal artery 
occlusion was considered. Assessment by an Internal Medicine doctor ruled out the 
presence of risk factors (cardiovascular and systemic) for this disease. The clinical 
presentation 16 weeks after initiation of INF therapy also contradicts this diagnostic 
possibility, since INF retinopathy can occur between 4 and 28 weeks after initiation of 
treatment, more frequently within the first 16 weeks (62% of cases) [4]. 
It is also remarkable that the picture presented by this patient had other atypical 
features, such as the absence of associated systemic disorders (hypertension, diabetes), 
ocular involvement, and persistent unilateral retinopathy even 6 months after 
discontinuation of INF treatment. In our literature review, only one case of unilateral 
INF-associated retinopathy was reported [3]. 
An insufficient vascular growth may significantly impact the nervous system, and 
angiogenesis is directly correlated with survival in patients with stroke [13]. The initial 
improvement in clinical symptoms with the use of a VEGF inhibitor could be associated 
with a decrease in vascular permeability and the disappearance of macular edema, but 
retinal ischemia may have been worsened by early antiangiogenic therapy (Avastin). The 
retrospective analysis suggests that early photocoagulation of the ischemic bed during the 
initial treatment could be decisive in preventing retinal and disc neovascularization.  
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Although the clinical course of INF-associated retinopathy is asymptomatic in most 
cases, there may be complications involving a risk for visual impairment, which is less 
common. However, the actual magnitude and severity of the consequences associated 
with INF therapy are to be determined in further prospective studies [7, 8]. 
 
 
 
Fig. 1. Fluorescein angiogram 24.0 seg, 3:53 and 8:32. Fluorescein angiography shows delayed arterial 
and venous filling, large areas of ischemia in the superior quadrants, retinal hemorrhages, periphlebitis, 
macular edema, upper trunk venous occlusion and lower trunk venous stasis associated with occlusion 
of the superior temporal arterial branch. 
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Fig. 2. OCT exhibited macular thickening (626 μm) secondary to diffuse edema and presence of 
microcysts. 
 
 
 
Fig. 3. OCT 2 months after the suspension of INF demonstrated decreased macular retinal thickness 
(322 μm) and partial resolution of edema. 
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Fig. 4. Control 4-month angiographies revealed large areas without capillary perfusion in the upper 
quadrants, neovascularization, and diffuse macular edema. 
 
 
 
Fig. 5. After 3 years of follow-up, fundoscopy revealed optic disc pallor, superior retinal atrophy, and 
macular hole. 
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